{"id":"https://openalex.org/W2135573233","doi":"https://doi.org/10.2217/fon.15.52","title":"Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity","display_name":"Nivolumab: Targeting PD-1 to Bolster Antitumor Immunity","publication_year":2015,"publication_date":"2015-03-23","ids":{"openalex":"https://openalex.org/W2135573233","doi":"https://doi.org/10.2217/fon.15.52","mag":"2135573233","pmid":"https://pubmed.ncbi.nlm.nih.gov/25798726"},"language":"en","primary_location":{"id":"doi:10.2217/fon.15.52","doi":"https://doi.org/10.2217/fon.15.52","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon.15.52","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"volume":null,"type":"review","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://doi.org/10.2217/fon.15.52","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5018401879","display_name":"Julie Renee Brahmer","orcid":"https://orcid.org/0000-0002-2443-8395","observed_orcids":["https://orcid.org/0000-0002-2443-8395"]},"institutions":[{"id":"https://openalex.org/I2799853436","display_name":"Johns Hopkins Medicine","ror":"https://ror.org/037zgn354","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Julie R Brahmer","raw_affiliation_strings":["Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA","institution_ids":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103085920","display_name":"Hans J. Hammers","orcid":"https://orcid.org/0000-0002-6224-4559","observed_orcids":["https://orcid.org/0000-0002-6224-4559"]},"institutions":[{"id":"https://openalex.org/I2799853436","display_name":"Johns Hopkins Medicine","ror":"https://ror.org/037zgn354","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hans Hammers","raw_affiliation_strings":["Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA","institution_ids":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5014494747","display_name":"Evan J. Lipson","orcid":"https://orcid.org/0000-0003-2976-0911","observed_orcids":["https://orcid.org/0000-0003-2976-0911"]},"institutions":[{"id":"https://openalex.org/I2799853436","display_name":"Johns Hopkins Medicine","ror":"https://ror.org/037zgn354","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I2799853436"]},{"id":"https://openalex.org/I4210164401","display_name":"Sidney Kimmel Comprehensive Cancer Center","ror":"https://ror.org/05m5b8x20","country_code":"US","type":"facility","lineage":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Evan J Lipson","raw_affiliation_strings":["Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA","institution_ids":["https://openalex.org/I2799853436","https://openalex.org/I4210164401"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.9804,"has_fulltext":false,"cited_by_count":200,"citation_normalized_percentile":{"value":0.94409734,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":89,"max":100},"biblio":{"volume":"11","issue":"9","first_page":"1307","last_page":"1326"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":1.0},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.9279999732971191},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9419999718666077},{"id":"https://openalex.org/keywords/antitumor-immunity","display_name":"antitumor immunity","score":0.9539999961853027},{"id":"https://openalex.org/keywords/t-cell-suppression","display_name":"T cell suppression","score":0.8769999742507935},{"id":"https://openalex.org/keywords/advanced-melanoma","display_name":"advanced melanoma","score":0.8119999766349792},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.9980000257492065},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":1.0},{"id":"https://openalex.org/keywords/dacarbazine","display_name":"dacarbazine","score":0.8410000205039978},{"id":"https://openalex.org/keywords/overall-survival","display_name":"overall survival","score":0.6930000185966492},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.8320000171661377},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.7570000290870667}],"concepts":[{"id":"https://openalex.org/C2780030458","wikidata":"https://www.wikidata.org/wiki/Q7041828","display_name":"Nivolumab","level":4,"score":0.987097978591919},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9042410850524902},{"id":"https://openalex.org/C2777658100","wikidata":"https://www.wikidata.org/wiki/Q180614","display_name":"Melanoma","level":2,"score":0.7144218683242798},{"id":"https://openalex.org/C2777472916","wikidata":"https://www.wikidata.org/wiki/Q1164529","display_name":"Renal cell carcinoma","level":2,"score":0.6925930380821228},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.5588880181312561},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5585346221923828},{"id":"https://openalex.org/C2776256026","wikidata":"https://www.wikidata.org/wiki/Q47912","display_name":"Lung cancer","level":2,"score":0.552758514881134},{"id":"https://openalex.org/C2780964509","wikidata":"https://www.wikidata.org/wiki/Q416975","display_name":"Dacarbazine","level":3,"score":0.5485010743141174},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4879150092601776},{"id":"https://openalex.org/C2781433595","wikidata":"https://www.wikidata.org/wiki/Q2459042","display_name":"Ipilimumab","level":4,"score":0.44404253363609314},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.44093233346939087},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.43981361389160156},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.4021751880645752},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.29403916001319885}],"mesh":[{"descriptor_ui":"D000077594","descriptor_name":"Nivolumab","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000911","descriptor_name":"Antibodies, Monoclonal","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D000970","descriptor_name":"Antineoplastic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000971","descriptor_name":"Antineoplastic Combined Chemotherapy Protocols","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000175","qualifier_name":"diagnosis","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":false},{"descriptor_ui":"D009369","descriptor_name":"Neoplasms","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D015415","descriptor_name":"Biomarkers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017321","descriptor_name":"Clinical Trials, Phase I as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017322","descriptor_name":"Clinical Trials, Phase II as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017326","descriptor_name":"Clinical Trials, Phase III as Topic","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056747","descriptor_name":"Immunomodulation","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000037","qualifier_name":"antagonists & inhibitors","is_major_topic":false},{"descriptor_ui":"D061026","descriptor_name":"Programmed Cell Death 1 Receptor","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.2217/fon.15.52","doi":"https://doi.org/10.2217/fon.15.52","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon.15.52","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},{"id":"pmid:25798726","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/25798726","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future oncology (London, England)","raw_type":"Journal Article"}],"best_oa_location":{"id":"doi:10.2217/fon.15.52","doi":"https://doi.org/10.2217/fon.15.52","is_oa":true,"landing_page_url":"https://doi.org/10.2217/fon.15.52","pdf_url":null,"source":{"id":"https://openalex.org/S174572715","display_name":"Future Oncology","issn_l":"1479-6694","issn":["1479-6694","1744-8301"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310321119","host_organization_name":"Future Medicine","host_organization_lineage":["https://openalex.org/P4310321119"],"host_organization_lineage_names":["Future Medicine"],"type":"journal"},"license":"cc-by-nc-nd","license_id":"https://openalex.org/licenses/cc-by-nc-nd","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Future Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":1.0}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":66,"referenced_works":["https://openalex.org/W165173872","https://openalex.org/W289544031","https://openalex.org/W622702216","https://openalex.org/W1657399034","https://openalex.org/W1801789563","https://openalex.org/W1901452696","https://openalex.org/W1914960099","https://openalex.org/W1977956466","https://openalex.org/W1980405393","https://openalex.org/W1990675339","https://openalex.org/W1992839193","https://openalex.org/W2000227671","https://openalex.org/W2010121426","https://openalex.org/W2016732129","https://openalex.org/W2016983859","https://openalex.org/W2031373281","https://openalex.org/W2041621047","https://openalex.org/W2052408138","https://openalex.org/W2063264144","https://openalex.org/W2066671159","https://openalex.org/W2083455294","https://openalex.org/W2095692889","https://openalex.org/W2097995306","https://openalex.org/W2099560139","https://openalex.org/W2099609050","https://openalex.org/W2100158834","https://openalex.org/W2107484016","https://openalex.org/W2109485845","https://openalex.org/W2109550365","https://openalex.org/W2112680373","https://openalex.org/W2115525561","https://openalex.org/W2117973220","https://openalex.org/W2119896120","https://openalex.org/W2123363005","https://openalex.org/W2127700366","https://openalex.org/W2128035403","https://openalex.org/W2129806226","https://openalex.org/W2130066229","https://openalex.org/W2131577873","https://openalex.org/W2133075384","https://openalex.org/W2135707184","https://openalex.org/W2139377071","https://openalex.org/W2140469315","https://openalex.org/W2141360391","https://openalex.org/W2143163879","https://openalex.org/W2148706732","https://openalex.org/W2150863468","https://openalex.org/W2151592384","https://openalex.org/W2160834915","https://openalex.org/W2187167680","https://openalex.org/W2223743646","https://openalex.org/W2237385549","https://openalex.org/W2244071142","https://openalex.org/W2286032567","https://openalex.org/W2305646079","https://openalex.org/W2336794604","https://openalex.org/W2404196663","https://openalex.org/W2442584486","https://openalex.org/W2473280483","https://openalex.org/W2476006635","https://openalex.org/W2513578542","https://openalex.org/W2522577924","https://openalex.org/W2526642223","https://openalex.org/W2600313033","https://openalex.org/W3011071920","https://openalex.org/W4285719527"],"related_works":["https://openalex.org/W2590359520","https://openalex.org/W2287821501","https://openalex.org/W1975992327","https://openalex.org/W2114972737","https://openalex.org/W2743004903","https://openalex.org/W2041578045","https://openalex.org/W2346278089","https://openalex.org/W2305646079","https://openalex.org/W2553256022","https://openalex.org/W1969888643"],"abstract_inverted_index":{"Nivolumab,":[0],"a":[1,106,114],"fully":[2],"human":[3],"IgG4":[4],"PD-1":[5,11,20],"immune":[6,16],"checkpoint":[7],"inhibitor":[8],"antibody,":[9],"blocks":[10],"and":[12,29,52,62,80,87],"can":[13],"restore":[14],"anticancer":[15],"responses":[17],"by":[18],"abrogating":[19],"pathway-mediated":[21],"T-cell":[22],"inhibition.":[23],"Nivolumab":[24,92,110],"is":[25,111],"approved":[26],"in":[27,54,98,105,127,132],"Japan":[28],"the":[30,33,139],"USA":[31],"for":[32,82],"treatment":[34],"of":[35,49,141,144],"patients":[36,55,101],"with":[37,56,102,113,129],"advanced":[38,57],"melanoma.":[39],"A":[40],"Phase":[41,107],"I":[42],"trial":[43],"reported":[44],"overall":[45,74],"objective":[46],"response":[47],"rates":[48,76],"17,":[50],"32":[51],"29%":[53],"non-small-cell":[58,83],"lung":[59,84],"cancer,":[60,85],"melanoma":[61,86,104],"renal":[63,88],"cell":[64,89],"carcinoma,":[65,90],"respectively,":[66],"which":[67],"included":[68],"many":[69],"heavily":[70],"pretreated":[71],"patients.":[72],"1-/2-year":[73],"survival":[75,95],"were":[77],"42%/24%,":[78],"63%/48%":[79],"70%/50%":[81],"respectively.":[91],"significantly":[93],"improved":[94],"versus":[96],"dacarbazine":[97],"previously":[99],"untreated":[100],"metastatic":[103],"III":[108],"trial.":[109],"associated":[112],"manageable":[115],"adverse":[116],"event":[117],"profile.":[118],"Numerous":[119],"clinical":[120],"trials":[121],"are":[122],"investigating":[123],"nivolumab":[124,142],"alone":[125],"or":[126],"combination":[128],"other":[130],"therapies":[131],"multiple":[133],"cancer":[134],"settings.":[135],"This":[136],"article":[137],"summarizes":[138],"development":[140],"as":[143],"November":[145],"2014.":[146]},"counts_by_year":[{"year":2026,"cited_by_count":10},{"year":2025,"cited_by_count":10},{"year":2024,"cited_by_count":15},{"year":2023,"cited_by_count":15},{"year":2022,"cited_by_count":13},{"year":2021,"cited_by_count":12},{"year":2020,"cited_by_count":27},{"year":2019,"cited_by_count":13},{"year":2018,"cited_by_count":22},{"year":2017,"cited_by_count":25},{"year":2016,"cited_by_count":29},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":1}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2016-06-24T00:00:00"}